Baggish Aaron L, Ackerman Michael J, Putukian Margot, Lampert Rachel
Cardiovascular Performance Program, Cardiology Division, Massachusetts General Hospital, Boston, MA.
Departments of Cardiovascular Medicine (Division of Heart Rhythm Services), Pediatric and Adolescent Medicine (Division of Pediatric Cardiology), and Molecular Pharmacology and Experimental Therapeutics (Windland Smith Rice Sudden Death Genomics Laboratory), Mayo Clinic, Rochester, MN.
Curr Sports Med Rep. 2019 Mar;18(3):76-81. doi: 10.1249/JSR.0000000000000575.
The diagnosis and management of cardiovascular disease (CVD) in competitive athletes represent a fundamental responsibility of the sports medicine community. Following the diagnosis of a CVD in a competitive athlete, it is the responsibility of the sports medicine team to delineate an effective treatment and management strategy that places the health and wellness of the athlete as the primary objective. An essential and often challenging aspect of this process is determining the appropriateness of continued participation (i.e., "return-to-play") in competitive athletics. Recently, a joint American Heart Association and American College of Cardiology Scientific Statement delineating sports eligibility supports a more patient-centered care model that supports shared decision making for clinicians and their patients/families. The present document was written to summarize the changing sports cardiology landscape with an aim of providing the cardiology and sports medicine communities with some practical approaches to eligibility decision making for competitive athletes with heart disease.
竞技运动员心血管疾病(CVD)的诊断与管理是运动医学领域的一项基本职责。在诊断出竞技运动员患有心血管疾病后,运动医学团队有责任制定有效的治疗和管理策略,将运动员的健康和福祉作为首要目标。这一过程中一个重要且常具挑战性的方面是确定继续参与竞技体育(即“重返赛场”)的适宜性。最近,美国心脏协会和美国心脏病学会联合发表的一份关于运动资格的科学声明支持了一种更以患者为中心的护理模式,该模式支持临床医生与其患者/家属共同做出决策。本文撰写的目的是总结运动心脏病学领域不断变化的情况,旨在为心脏病学和运动医学领域提供一些实用方法,用于为患有心脏病的竞技运动员做出资格决策。